Global pharma major Lupin Limited on Friday announced that its South African subsidiary, Pharma Dynamics, has acquired nine brands along with their associated trademarks, from the Medical Nutritional Institute SA (MNI) in South Africa, through a partnership deal with ImpiloVest, a South African investment firm.
According to the company’s statement, the acquired brands include AntaGolin, RyChol, NeuroVance, SkinVance, FlamLeve, Rheumalin, SleepVance, ImmunoVance, and OviVance. These products cater to a range of health issues such as metabolic syndrome, insulin resistance, cognitive function, skin health, inflammation, joint care, sleep quality, immune support, and women’s hormonal well-being.
MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome.
“This acquisition is a major step for Lupin to expand our footprint in the Complementary and Alternative Medicines sector. MNI’s innovative plant-based products align perfectly with our goal to provide holistic and sustainable healthcare solutions to our patients in South Africa,” Thierry Volle, President EMEA, Lupin said.
This acquisition will enable Lupin gain access to MNI’s wide portfolio of nine brands, that are marketed as branded products in the South African retail sector.
“There is a growing trend of patients seeking proactive healthcare solutions. This acquisition broadens our product range by concentrating on metabolic diseases such as cardiovascular disease, diabetes, and neuroscience, thereby enhancing patient health and well-being,” Erik Roos, CEO, Pharma Dynamics said.
